Alzheimer's disease (dementia)

Alzheimer's disease (dementia)
Name	Alzheimer's disease (dementia)
Field	Neurology, Geriatrics, Psychiatry
Symptoms	Memory loss, cognitive decline, behavioral changes
Onset	Usually after age 65
Causes	Multifactorial: amyloid plaques, tau tangles, vascular factors, genetics
Risks	Age, Apolipoprotein E genotype, Down syndrome, cardiovascular disease
Medication	Cholinesterase inhibitors, NMDA receptor antagonists
Frequency	Increasing with aging populations

Alzheimer's disease (dementia) Alzheimer's disease (dementia) is a progressive neurodegenerative condition characterized by declining memory, cognition, and functional abilities. Clinically managed across settings such as Mayo Clinic, Johns Hopkins Hospital, and Karolinska Institutet, it presents major challenges for patients, families, and health systems including World Health Organization and national health services like NHS (England). Research efforts span institutions including National Institutes of Health, Alzheimer's Association (United States), University of Oxford, and industry partners such as Roche and Biogen.

Introduction

Alzheimer's disease (dementia) was first described in the early 20th century through case studies by clinicians affiliated with institutions like University of Munich and influenced later work at Institute of Neurology, London. Modern classification is informed by guidelines from bodies such as American Psychiatric Association and World Health Organization. Large cohort studies from Framingham Heart Study, Rotterdam Study, and UK Biobank have defined incidence, while trials at centers including Massachusetts General Hospital and Mayo Clinic test interventions. Public figures affected include patients followed by media outlets like BBC and The New York Times, prompting policy responses from agencies including Centers for Disease Control and Prevention.

Symptoms and progression

Early symptoms often include episodic memory deficits observed in clinical services at Mount Sinai Health System, with progression to language and executive dysfunction treated by specialists at Karolinska University Hospital and Cleveland Clinic. Behavioral and psychological symptoms may require consultation with teams at UCLA Health or Johns Hopkins Medicine, and noncognitive features can lead to institutional care in facilities such as Veterans Health Administration homes. Staging systems from researchers at Albert Einstein College of Medicine and scoring scales developed at St. Louis Medical Center are used in trials funded by National Institute on Aging to track mild cognitive impairment through moderate and severe stages.

Causes and risk factors

Multiple risk factors have been identified in longitudinal studies at Harvard Medical School, Columbia University Irving Medical Center, and University of California, San Francisco. Genetic contributors include variants in Apolipoprotein E alleles and rare mutations studied at Cold Spring Harbor Laboratory and Massachusetts Institute of Technology. Down syndrome populations followed at Yale School of Medicine exhibit increased risk. Vascular risk factors documented by researchers at Johns Hopkins Bloomberg School of Public Health and Imperial College London—including hypertension and diabetes—modify risk, as do lifestyle factors investigated in cohorts like Nurses' Health Study.

Pathophysiology

Neuropathological hallmarks—extracellular amyloid-beta plaques and intracellular tau tangles—were elucidated in neuropathology units at Charité – Universitätsmedizin Berlin and Institute of Neurology, UCL. Molecular pathways involving synaptic dysfunction, neuroinflammation mediated by microglia studied at Salk Institute, and mitochondrial impairment explored at Max Planck Society drive neuronal loss. Biomarker advances from groups at University of Gothenburg and University of Pennsylvania include cerebrospinal fluid assays and PET imaging using ligands developed in collaborations with companies like GE Healthcare and Siemens Healthineers.

Diagnosis

Diagnostic criteria evolved through consensus statements from organizations such as American Academy of Neurology and International Working Group on Neurodegenerative Diseases. Cognitive testing batteries used in clinics at Mount Sinai and research centers at Stanford University include tools validated against autopsy series at MRC Cognition and Brain Sciences Unit. Neuroimaging with MRI and PET is performed at centers including Massachusetts General Hospital and MAYO Clinic, while fluid biomarkers are analyzed in laboratories at Broad Institute and Vanderbilt University Medical Center to increase diagnostic accuracy.

Treatment and management

Current pharmacologic treatments—cholinesterase inhibitors and NMDA receptor antagonists—are prescribed in practice settings such as Cleveland Clinic and monitored by specialists at Mayo Clinic. Disease-modifying therapies have been evaluated in trials sponsored by Biogen, Eli Lilly and Company, and Roche with regulatory decisions by agencies like U.S. Food and Drug Administration and European Medicines Agency. Nonpharmacologic interventions including cognitive rehabilitation and caregiver support are implemented by organizations like Alzheimer's Association (United States) and community programs in cities such as New York City and London. Palliative care coordination often involves teams at St Christopher's Hospice and hospital programs at Johns Hopkins Medicine.

Epidemiology and impact

Prevalence and incidence estimates derive from population studies in regions covered by European Commission research consortia, the Global Burden of Disease studies, and national registries such as those maintained by Statistics Canada and Office for National Statistics (UK). Aging demographics in countries like Japan, Italy, and United States drive projected increases, with economic analyses by institutions including World Bank estimating healthcare and caregiver costs. Advocacy and policy initiatives by groups such as Alzheimer's Society (UK) and Global Alzheimer’s Platform Foundation aim to coordinate research, clinical care, and social support.

Category:Neurodegenerative diseases